| 臺大學術典藏 |
2020-09-29T01:47:44Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Yeh K.-H.; Cheng A.-L.; Yang J.C.-H.; Kao H.-F.; Chen I.-C.; Hsu C.; Chang S.-Y.; Chien S.-F.; YEE-CHUN CHEN; Hu F.-C. |
| 臺大學術典藏 |
2020-09-23T08:35:42Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang W.-C.;Xiao F.;Shih J.-Y.;Ho C.-C.;Ya-Fang Chen;Tseng H.-M.;Chen K.-Y.;Liao W.-Y.;Yu C.-J.;Yang J.C.-H.;Kuo S.-H.;Cheng J.C.-H.;Yang P.-C.;Hsu F.-M.; Yang W.-C.; Xiao F.; Shih J.-Y.; Ho C.-C.; YA-FANG CHEN; Tseng H.-M.; Chen K.-Y.; Liao W.-Y.; Yu C.-J.; Yang J.C.-H.; Kuo S.-H.; Cheng J.C.-H.; Yang P.-C.; Hsu F.-M. |
| 臺大學術典藏 |
2020-08-18T07:28:24Z |
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer
|
Yang J.C.-H.; YU-FEN WANG; Lin Y.-T.; Yu C.-J.; Wu S.-G.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:55Z |
Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach
|
Lu S.; Thongprasert S.; Salto-Tellez M.; Tsao M.-S.; JIN-YUAN SHIH; Chang G.-C.; Au J.S.-K.; Chou T.-Y.; Lee J.-S.; Shi Y.-K.; Radzi A.; Kang J.-H.; Kim S.-W.; Tan S.-Y.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-08-13T06:33:49Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Miller V.A.; Yang P.-C.; Lorence R.M.; Cong X.J.; Shahidi M.; Dudek A.Z.; Sequist L.V.; Yang J.C.H.; JIN-YUAN SHIH; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L. |
| 臺大學術典藏 |
2020-08-13T06:33:49Z |
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer
|
Chang G.-C.; JIN-YUAN SHIH; Yu S.-L.; Yang P.-C.; Ho B.-C.; Chan W.-K.; Yang J.C.-H.; Kuo M.-L.; Su K.-Y.; Chen H.-Y.; Li K.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:47Z |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer
|
Yang J.C.-H.; Ho C.-C.; Chen K.-Y.; JIN-YUAN SHIH; Wu M.; Chen J.-H.; Liao W.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-13T06:33:46Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; Chang Y.-L.; JIN-YUAN SHIH; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; Yang P.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:46Z |
Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas
|
Lin C.-H.; Cheng A.-L.; Wu S.-G.; JIN-YUAN SHIH; Wu P.-F.; Huang W.-C.; Yang J.C.-H.; Lu Y.-S. |
| 臺大學術典藏 |
2020-08-13T06:33:46Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; Chang Y.-C.; Yu C.-J.; JIN-YUAN SHIH; Lin C.-C.; Chen K.-Y.; Ho C.-C.; Laio W.-Y.; Yang P.-C.; Yang J.C.-H.; Lee J.-H. |
| 臺大學術典藏 |
2020-08-13T06:33:44Z |
Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis
|
JIN-YUAN SHIH; Yang J.C.H.; Yu C.-J.; Yang P.-C.; Chen K.-Y.; Chen J.-H.; Hsu C.-L. |
| 臺大學術典藏 |
2020-08-13T06:33:44Z |
IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer
|
JIN-YUAN SHIH; Yang J.C.-H.; Yu S.-L.; Liu Y.-N.; Chang T.-H.; Tsai M.-F.; Wu S.-G.; Tsai T.-H.; Chen H.-Y. |
| 臺大學術典藏 |
2020-08-13T06:33:43Z |
Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy
|
Liao B.C.; Lin C.C.; JIN-YUAN SHIH; Yang J.C.H. |
| 臺大學術典藏 |
2020-08-13T06:33:40Z |
The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases
|
Chiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; JIN-YUAN SHIH; Lin Z.-Z.; Lan K.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2020-08-13T06:33:40Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
Liao B.-C.; Lee J.-H.; Lin C.-C.; Chen Y.-F.; Chang C.-H.; Ho C.-C.; JIN-YUAN SHIH; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-08-13T06:33:40Z |
Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene
|
Yang J.C.-H.; JIN-YUAN SHIH; Wu H. |
| 臺大學術典藏 |
2020-08-13T06:33:39Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Chen L.-Y.;Molina-Vila M.A.;Ruan S.-Y.;Su K.-Y.;Liao W.-Y.;Yu K.-L.;Ho C.-C.;Jin-Yuan Shih;Yu C.-J.;Yang J.C.H.;Rosell R.;Yang P.-C.; Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; Liao W.-Y.; Yu K.-L.; Ho C.-C.; JIN-YUAN SHIH; Yu C.-J.; Yang J.C.H.; Rosell R.; Yang P.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:39Z |
Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations
|
Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; Chang Y.-L.; Yu C.-J.; Yang J.C.-H.; Yang P.-C.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-08-13T06:33:33Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Yang J.C.-H.; Thress K.S.; Huang D.D.-R.; Bai Y.-Y.; Chang Y.-L.; Hsieh M.-S.; Su K.-Y.; Tsai T.-H.; Lee J.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; JIN-YUAN SHIH; Yu C.-J.; Lin C.-C.;Jin-Yuan Shih;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-08-13T06:33:33Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Chen K.-Y.; Liao W.-Y.; Yu C.-J.; Yang J.C.-H.; Kuo S.-H.; Cheng J.C.-H.; Yang P.-C.; Hsu F.-M.; Tseng H.-M.; Chen Y.-F.; Yang W.-C.; Xiao F.; JIN-YUAN SHIH; Ho C.-C.; Yang W.-C.;Xiao F.;Jin-Yuan Shih;Ho C.-C.;Chen Y.-F.;Tseng H.-M.;Chen K.-Y.;Liao W.-Y.;Yu C.-J.;Yang J.C.-H.;Kuo S.-H.;Cheng J.C.-H.;Yang P.-C.;Hsu F.-M. |
| 臺大學術典藏 |
2020-08-13T06:33:31Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients
|
Ho C.-C.; JIN-YUAN SHIH; Yu C.-J.; Yang J.C.-H.; Liao W.-Y.; Lin C.-C.; Lee J.-H.; Hsiue E.H.-C.; Wu T.-H.; Wu T.-H.;Hsiue E.H.-C.;Lee J.-H.;Lin C.-C.;Liao W.-Y.;Ho C.-C.;Jin-Yuan Shih;Yu C.-J.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-08-13T06:33:30Z |
Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion
|
JIN-YUAN SHIH; Yang J.C.-H.; Yu C.-J.; Liu Y.-N.; Wu S.-G.; Wu S.-G.;Liu Y.-N.;Yu C.-J.;Yang J.C.-H.;Jin-Yuan Shih |
| 臺大學術典藏 |
2020-08-13T06:33:27Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.;Ko J.-C.;Yang J.C.-H.;Jin-Yuan Shih; Liang S.-K.; Ko J.-C.; Yang J.C.-H.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-08-13T06:33:27Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yang J.C.-H.; Yu C.-J.; JIN-YUAN SHIH; Lin Z.-Z.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H. |
| 臺大學術典藏 |
2020-08-13T06:33:24Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Tsai T.-H.; Chen K.-Y.; Ho C.-C.; Liao W.-Y.; Yang C.-Y.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Jin-Yuan Shih;Yang J.C.-H.;Yu C.-J.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; JIN-YUAN SHIH; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-13T06:33:24Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yu C.-J.; Yang J.C.-H.; JIN-YUAN SHIH; Lin C.-C.; Lee J.-H.; Hsu W.-H.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu C.-L.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Jin-Yuan Shih;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H. |
| 臺大學術典藏 |
2020-08-13T05:24:15Z |
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
|
Yang C.-Y.; Tsai T.-H.; Ho C.-C.; Liao W.-Y.; Jan I.-S.; Chen K.-Y.; JANN-YUAN WANG; Ruan S.-Y.; Yu C.-J.; Yang J.C.H.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-12T08:25:25Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; Yang P.-C.; Chen Y.-F.; Hsieh M.-S.; SHANG-GIN WU; Chang Y.-L.; Shih J.-Y.; Liu Y.-N.; Tsai M.-F. |
| 臺大學術典藏 |
2020-08-12T08:25:24Z |
IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer
|
Chen H.-Y.; Yu S.-L.; Yang J.C.-H.; Shih J.-Y.; Tsai T.-H.; SHANG-GIN WU; Tsai M.-F.; Chang T.-H.; Liu Y.-N. |
| 臺大學術典藏 |
2020-08-12T08:25:24Z |
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer
|
Lin Y.-T.; Wang Y.-F.; Yang J.C.-H.; Yu C.-J.; SHANG-GIN WU; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-08-12T08:25:23Z |
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
|
SHANG-GIN WU; Liu Y.-N.; Tsai M.-F.; Chang Y.-L.; Yu C.-J.; Yang P.-C.; Yang J.C.-H.; Wen Y.-F.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-12T08:25:23Z |
Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations
|
Chen Y.-F.; Hsieh M.-S.; SHANG-GIN WU; Chang Y.-L.; Yu C.-J.; Yang J.C.-H.; Yang P.-C.; Shih J.-Y.; Chen Y.-F.;Hsieh M.-S.;Shang-Gin Wu;Chang Y.-L.;Yu C.-J.;Yang J.C.-H.;Yang P.-C.;Shih J.-Y. |
| 臺大學術典藏 |
2020-08-12T08:25:23Z |
Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion
|
Tsai T.-H.;Shang-Gin Wu;Hsieh M.-S.;Yu C.-J.;Yang J.C.H.;Shih J.-Y.; Tsai T.-H.; SHANG-GIN WU; Hsieh M.-S.; Yu C.-J.; Yang J.C.H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-12T08:25:21Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer
|
Lin Y.-T.;Liu Y.-N.;Shang-Gin Wu;Yang J.C.-H.;Shih J.-Y.; Lin Y.-T.; Liu Y.-N.; SHANG-GIN WU; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-12T07:57:21Z |
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
|
Tsai T.-H.; Yang C.-Y.; Ho C.-C.; Liao W.-Y.; Jan I.-S.; Chen K.-Y.; Wang J.-Y.; SHENG-YUAN RUAN; Yu C.-J.; Yang J.C.H.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-12T07:57:16Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Chen L.-Y.; Molina-Vila M.A.; SHENG-YUAN RUAN; Su K.-Y.; Liao W.-Y.; Yu K.-L.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.H.; Rosell R.; Yang P.-C. |
| 臺大學術典藏 |
2020-08-12T06:34:29Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; CHONG-JEN YU; Chen K.-Y.; Shih J.-Y.; Ho C.-C.; Liao W.-Y.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Chong-Jen Yu |
| 臺大學術典藏 |
2020-08-12T06:34:19Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; CHONG-JEN YU; Liao W.-Y.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Chong-Jen Yu |
| 臺大學術典藏 |
2020-08-12T06:34:19Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU; Lin Y.-T.; Chen J.-S.; Liao W.-Y. |
| 臺大學術典藏 |
2020-08-12T06:34:15Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Hsu C.-C.; Wu C.-T.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Yang C.-Y.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2020-08-12T02:50:46Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Shih J.-Y.; CHAO-CHI HO; Yu K.-L.; Chen L.-Y.;Molina-Vila M.A.;Ruan S.-Y.;Su K.-Y.;Liao W.-Y.;Yu K.-L.;Chao-Chi Ho;Shih J.-Y.;Yu C.-J.;Yang J.C.H.;Rosell R.;Yang P.-C.; Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; Liao W.-Y.; Yu C.-J.; Yang J.C.H.; Rosell R.; Yang P.-C. |
| 臺大學術典藏 |
2020-08-12T02:50:46Z |
Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer
|
Lu S.-L.;Hsu F.-M.;Chen K.-Y.;Chao-Chi Ho;Yang J.C.-H.;Cheng J.C.-H.; Lu S.-L.; Hsu F.-M.; Chen K.-Y.; CHAO-CHI HO; Yang J.C.-H.; Cheng J.C.-H. |
| 臺大學術典藏 |
2020-08-12T02:50:42Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Lin C.-C.; Yang J.C.H.; Yu C.-J.; Lin Z.-Z.; Chen J.-S.; Yao Z.-H.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.; Yao Z.-H.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T02:50:40Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.;Shih J.-Y.;Yu C.-J.;Chao-Chi Ho;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; CHAO-CHI HO; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-08-12T02:50:40Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang W.-C.; Xiao F.; Shih J.-Y.; CHAO-CHI HO; Chen Y.-F.; Tseng H.-M.; Chen K.-Y.; Liao W.-Y.; Yu C.-J.; Yang J.C.-H.; Kuo S.-H.; Cheng J.C.-H.; Yang P.-C.; Hsu F.-M.; Yang W.-C.;Xiao F.;Shih J.-Y.;Chao-Chi Ho;Chen Y.-F.;Tseng H.-M.;Chen K.-Y.;Liao W.-Y.;Yu C.-J.;Yang J.C.-H.;Kuo S.-H.;Cheng J.C.-H.;Yang P.-C.;Hsu F.-M. |
| 臺大學術典藏 |
2020-08-12T02:50:39Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients
|
Lee J.-H.; Lin C.-C.; Liao W.-Y.; CHAO-CHI HO; Shih J.-Y.; Yu C.-J.; Yang J.C.-H.; Wu T.-H.; Hsiue E.H.-C.; Wu T.-H.;Hsiue E.H.-C.;Lee J.-H.;Lin C.-C.;Liao W.-Y.;Chao-Chi Ho;Shih J.-Y.;Yu C.-J.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-08-12T02:50:37Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Hsu C.-L.; CHAO-CHI HO; Liao W.-Y.; Chen J.-S.; Lin Y.-T.; Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Chao-Chi Ho;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T02:50:36Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Wu C.-T.; Chang Y.-L.; Yang C.-Y.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y. |
| 臺大學術典藏 |
2020-08-12T02:50:36Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yang J.C.-H.; Yu C.-J.; Yao Z.-H.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C. |
| 臺大學術典藏 |
2020-08-12T02:50:35Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
